Completed PHASE2 NCT00270634

Study of ISA247 (Voclosporin) in De Novo Renal Transplantation

A Phase IIb, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 (Voclosporin) and Tacrolimus (Prograf®) in De Novo Renal Transplant Patients

Sponsor: Aurinia Pharmaceuticals Inc.

Conditions Kidney Diseases

Interventions Voclosporin tacrolimus

Updated 9 times since 2017 Last updated: Feb 11, 2013 Started: Jan 31, 2006 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

A PHASE2 clinical study on Kidney Diseases, this trial is completed. The trial is conducted by Aurinia Pharmaceuticals Inc. and has accumulated 9 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aurinia Pharmaceuticals Inc.

Data source: Aurinia Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Buffalo, United States , Charleston, United States , Chicago, United States , Cincinnati, United States , Dallas, United States , Denver, United States and 26 more locations